StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note issued to investors on Thursday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 2.7 %
Shares of NASDAQ TTNP opened at $3.85 on Thursday. The business has a 50-day moving average of $5.54 and a two-hundred day moving average of $6.02. Titan Pharmaceuticals has a 1 year low of $3.63 and a 1 year high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- The How And Why of Investing in Oil Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Do S&P 500 Stocks Tell Investors About the Market?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
